The second quarter and half year results of Novartis AG show a pharmaceutical company in transition rather than one where the figures are strictly comparable with the previous period.
Vasant Narasimhan, the Harvard University-educated doctor who became chief executive in February 2018 has been busy with his plans to streamline the company into a leader of advanced therapies, supported by digitally-backed research.